SEOM Clinical Guideline of management of soft-tissue sarcoma (2020).

{"article_title":"SEOM Clinical Guideline of management of soft-tissue sarcoma (2020).","author":"de Juan Ferr\u00e9 A, \u00c1lvarez \u00c1lvarez R, Casado Herr\u00e1ez A, Cruz Jurado J, Estival Gonz\u00e1lez A, Mart\u00edn-Broto J, Mart\u00ednez Mar\u00edn V, Moreno Vega A, Sebio Garc\u00eda A, Valverde Morales C","journal_title":"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico","issn":"1699-3055","isbn":"","publication_date":"2021-05-01","volume":"23","issue":"5","first_page":"922","page_count":"","accession_number":"33405052","doi":"","publisher":"Springer","doctype":"Journal Article","subjects":"Spain; Sarcoma diagnosis; Sarcoma therapy; Soft Tissue Neoplasms diagnosis; Soft Tissue Neoplasms therapy; Anthracyclines therapeutic use; Antineoplastic Agents therapeutic use; Checklist; Chemotherapy, Adjuvant methods; Dermatofibrosarcoma therapy; Female; Fibromatosis, Aggressive genetics; Fibromatosis, Aggressive therapy; Humans; Magnetic Resonance Imaging; Male; Medical Oncology; Neoadjuvant Therapy methods; Radiotherapy methods; Retroperitoneal Neoplasms therapy; Sarcoma diagnostic imaging; Sarcoma pathology; Societies, Medical; Soft Tissue Neoplasms diagnostic imaging; Soft Tissue Neoplasms pathology; Solitary Fibrous Tumors drug therapy; Spain; Tomography, X-Ray Computed; Uterine Neoplasms therapy","interest_area":["Oncology"],"abstract":"Soft-tissue sarcomas constitute an uncommon and heterogeneous group of tumors of mesenchymal origin. Diagnosis, treatment, and management should be performed by an expert multidisciplinary team. MRI\/CT of the primary tumor and biopsy is mandatory before any treatment. Wide surgical resection with tumor-free tissue margin is the mainstay for localized disease. Radiotherapy is indicated in large, deep, high-grade tumors, or after marginal resection not suitable for re-excision. Perioperative chemotherapy should be discussed for high-risk sarcomas of the extremities and trunk-wall. In the case of oligometastatic disease, patients should be considered for local therapies. First-line treatment with anthracyclines (or in combination with ifosfamide) is the treatment of choice. Other drugs have shown activity in second-line therapy and in specific histological subtypes but options are limited and thus, a clinical trial should always be discussed.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=33405052","isPdfLink":true,"isSAML":false,"an":"33405052","number_other":"","type_pub":"","issn_electronic":"1699-3055","languages":"English","language":"eng","date_entry":"","date_update":"","titleSource":"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2021 May; Vol. 23 (5), pp. 922-930. Date of Electronic Publication: 2021 Jan 06.","date_pub_cy":"","type_document":"","contract_publisher":"","authored_on":"2021-05-01","description":"Soft-tissue sarcomas constitute an uncommon and heterogeneous group of tumors of mesenchymal origin. Diagnosis, treatment, and management should be performed by an expert multidisciplinary team. MRI\/CT of the primary tumor and biopsy is mandatory before any treatment. Wide surgical resection with tumor-free tissue margin is the mainstay for localized disease. Radiotherapy is indicated in large, deep, high-grade tumors, or after marginal resection not suitable for re-excision. Perioperative chemotherapy should be discussed for high-risk sarcomas of the extremities and trunk-wall. In the case of oligometastatic disease, patients should be considered for local therapies. First-line treatment with anthracyclines (or in combination with ifosfamide) is the treatment of choice. Other drugs have shown activity in second-line therapy and in specific histological subtypes but options are limited and thus, a clinical trial should always be discussed.","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=33405052&authtype=shib&custid=ns346513&group=main&profile=eds","no_of_pages":"","authored_by":"de Juan Ferr\u00e9 A, \u00c1lvarez \u00c1lvarez R, Casado Herr\u00e1ez A, Cruz Jurado J, Estival Gonz\u00e1lez A, Mart\u00edn-Broto J, Mart\u00ednez Mar\u00edn V, Moreno Vega A, Sebio Garc\u00eda A, Valverde Morales C","header":{"DbId":"mdl","DbLabel":"MEDLINE Ultimate","An":"33405052","RelevancyScore":"892","PubType":"Academic Journal","PubTypeId":"academicJournal","PreciseRelevancyScore":"891.547546386719"},"plink":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=33405052&authtype=shib&custid=ns346513&group=main&profile=eds","physicalDescription":{"Pagination":{"StartPage":"922"}},"additionalInfo":{"Authored_By":"de Juan Ferr\u00e9 A, \u00c1lvarez \u00c1lvarez R, Casado Herr\u00e1ez A, Cruz Jurado J, Estival Gonz\u00e1lez A, Mart\u00edn-Broto J, Mart\u00ednez Mar\u00edn V, Moreno Vega A, Sebio Garc\u00eda A, Valverde Morales C","Journal_Info":"Publisher: Country of Publication: Italy NLM ID: 101247119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1699-3055 (Electronic) Linking ISSN: 1699048X NLM ISO Abbreviation: Clin Transl Oncol Subsets: MEDLINE","Publication_Type":"Journal Article; Practice Guideline","Published_Date":"2021-05-01","Source":"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2021 May; Vol. 23 (5), pp. 922-930. Date of Electronic Publication: 2021 Jan 06.","Languages":"English","Electronic_ISSN":"1699-3055","MeSH_Terms":"Sarcoma\/*diagnosis , Sarcoma\/*therapy , Soft Tissue Neoplasms\/*diagnosis , Soft Tissue Neoplasms\/*therapy, Anthracyclines\/therapeutic use ; Antineoplastic Agents\/therapeutic use ; Checklist ; Chemotherapy, Adjuvant\/methods ; Dermatofibrosarcoma\/therapy ; Female ; Fibromatosis, Aggressive\/genetics ; Fibromatosis, Aggressive\/therapy ; Humans ; Magnetic Resonance Imaging ; Male ; Medical Oncology ; Neoadjuvant Therapy\/methods ; Radiotherapy\/methods ; Retroperitoneal Neoplasms\/therapy ; Sarcoma\/diagnostic imaging ; Sarcoma\/pathology ; Societies, Medical ; Soft Tissue Neoplasms\/diagnostic imaging ; Soft Tissue Neoplasms\/pathology ; Solitary Fibrous Tumors\/drug therapy ; Spain ; Tomography, X-Ray Computed ; Uterine Neoplasms\/therapy","Subjects":"Anthracyclines therapeutic use, Antineoplastic Agents therapeutic use, Checklist, Chemotherapy, Adjuvant methods, Dermatofibrosarcoma therapy, Female, Fibromatosis, Aggressive genetics, Fibromatosis, Aggressive therapy, Humans, Magnetic Resonance Imaging, Male, Medical Oncology, Neoadjuvant Therapy methods, Radiotherapy methods, Retroperitoneal Neoplasms therapy, Sarcoma diagnostic imaging, Sarcoma pathology, Societies, Medical, Soft Tissue Neoplasms diagnostic imaging, Soft Tissue Neoplasms pathology, Solitary Fibrous Tumors drug therapy, Spain, Tomography, X-Ray Computed, Uterine Neoplasms therapy, Sarcoma diagnosis, Sarcoma therapy, Soft Tissue Neoplasms diagnosis, Soft Tissue Neoplasms therapy","Title_Abbreviations":"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico","Volume":"23"}}